Octrea Adverse Reactions

Adverse drug reactions are listed by Medra system organ class. The adverse drug reactions are ranked by frequency, with the most frequency first, using the following convention: very common (≥ 1/10) common (≥ 1/100, < 1/10); uncommon (≥ 1/1000); rare (≥ 1/10,000, < 1/1000) very rare (< 1/10,000).
Common adverse effects of octreotide include GI discomfort e.g. diarrhea, loose stools, abdominal discomfort, bloating, constipation, nausea and vomiting were each seen in 34% to 61% of acromegaly patient in US studies, although only 2.6% of the patients discontinued therapy. These symptoms were seen in 5% to 10% of patient with other order.
In general, GI effects of octreotide injection develop during the first days to weeks of therapy and diminish with time. GI effects may be minimized by avoiding meals around the time of octreotide administration.
Cardiac disorders: In acromegalic patient, bradycardia (25%) and arrhythmias developed during octreotide therapy (9%). Chest pain, congestive heart failure, hypertensive reaction, ischemia, orthostatic blood pressure decrease, palpitation, shortness of breath, tachycardia, thrombophlebitis were reported less than 1%.
Hepatobiliary disorders: Hepatitis, increased liver enzyme, and jaundice has been uncommonly reported.
In very rare instances, acute pancreatitis has been reported within the first hours or days of octreotide (s.c.) treatment and resolved on withdrawal of the drug.
Dermatologic effects: Bruising, hair loss, pruritus is common in patient receiving octreotide. Rash and urticaria were also reported.
Central nervous system disorders: Fatigue, headache, malaise, and dizziness are commonly reported. Anxiety, seizures, drowsiness, vertigo, hyperesthesia, head pounding, insomnia, irritability, forgetfulness, malaise, nervousness, shakiness, tremor, numbness or Bell's palsy has been uncommonly reported.
Hypersensitivity: Anaphylactic reactions, including anaphylactic shock have been reported in patients receiving octreotide.
Endocrine disorders: Hypoglycemia and hyperglycemia occurred in patients receiving octreotide. In patient treated with octreotide, hypothyroidism or goiter was reported.
Respiratory disorders: Pneumonia, pulmonary nodule, status asthmaticus are uncommonly reported. Dyspnea reported very rare.
Other adverse effects: Common: flu-like symptoms, pollakiuria, visual disturbance.
Uncommon: shortness of breath, weight loss, and increased creatine kinase (CK, creatine phosphokinase, CPK).